Inhibition of TNF-α synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis

Medical Hypotheses

Volumn 53, Issue 1, 1999, Pages 76-77

  Sastry, P S R K ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCYCLIC KETONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0033166025     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0719     Document Type: Article

References (14)

1. Matthews W. B. Course and prognosis. Matthews W. B., Compston A., Allen I. V., Martyn C. N. McAlpine's Multiple Sclerosis, 2nd edn. 1991;139-163 Churchill Livingstone, Edinburgh.
2. Selmaz K. W., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 23:1988;339-346.
3. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor nercrosis factor α Proc Natl Acad Sci USA. 92:1995;11294-11298.
4. Sharief M. K., Thompson E. J. In vivo relationship of tumor necrosis factor a to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol. 38:1992;27-33.
5. Brosnan C. F., Raine C. S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:1996;243-257.
6. Sommer N., Loschmann P. A., Northoff G. H. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1:1995;244-248.
7. Lenz W. Thalidomide and congenital abnormalities. Lancet. 1:1962;4-5.
8. Sheskin J. Thalidomide in treatment of lepra reactions. Clin Pharmacol Ther. 6:1968;303-306.
9. Iyer C. G. S., Languillon J., Ramunujam K. WHO coordinated short term double blind trial with thalidomide in the treatment of acute lepra reaction in male lepromatous patients. Bull WHO. 45:1971;719-732.
10. Vogelsang G. B., Hess A. D., Ling T. Thalidomide therapy of chronic graft-versus-host disease. Blood. 70:1987;315(a).
11. Jacobson J. M., Greenspan J. S., Spritzler J. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 336:1997;1487-1493.
12. Peterson P. K., Hu S., Sheng W. S., Kravitz F. H., Molitor T. W., Chatterjee D., Chao C. C. Thalidomide inhibits tumor necrosis factor-a production by lipopolysacharide and lipoarabinomannan-stimulated human microglial cells. J Infect Dis. 172:1995;1137-1140.
13. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor - enhancing mRNA degradation. J Exp Med. 177:1993;1675-1680.
14. Fassas A., Anagnostopoulos A., Kazis A. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 20:1997;631-638.